Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience.

摘要: Aripiprazole is the newest atypical antipsychotic (AA) drug to be released in US. It only AA that a partial agonist at D2 and 5HT1a receptors an antagonist 5HT2a receptors. also has high 5HT2/D2 ratio may therefore carry low risk of extrapyramidal side effects alleviate psychosis Parkinson-vulnerable populations. We report our preliminary experience 8 patients with probable Parkinson disease (PD) treated aripiprazole for drug-induced psychosis. Two were neuroleptic-naive, 5 "quetiapine failures", 1 patient was switched from olanzapine aripiprazole. started mg 10 day slowly increased over 3 7 days until or improvement occurred. Only 2 out experienced near complete resolution their using The other six discontinued within 40 days, whom due motor worsening. Our mixed but not very encouraging. Controlled studies are needed evaluate parkinsonian patients.